ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics N.V. (PRQR) Healthcare & Pipeline Overview

ProQR Therapeutics N.V. is a biopharmaceutical company specializing in RNA-based therapeutics for genetic disorders, focusing on rare diseases with high unmet needs. Their innovative Axiomer RNA base-editing platform and clinical programs targeting LCA10 and Usher syndrome position them in the competitive biotechnology landscape.

What Is the Investment Thesis for PRQR?

ProQR Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on RNA-based therapeutics for rare genetic disorders offers significant potential, particularly with its lead candidates, sepofarsen and ultevursen, in Phase II/III trials. Positive clinical trial results could serve as major catalysts, driving substantial stock appreciation. However, the inherent risks of drug development, including clinical trial failures and regulatory hurdles, cannot be ignored. The company's negative profit margin of -264.9% underscores its reliance on future product approvals and partnerships for revenue generation. Successful commercialization of its pipeline, coupled with strategic collaborations, is crucial for long-term value creation. Investors should carefully weigh the potential upside against the significant risks associated with ProQR's development-stage business model.

Based on FMP financials and quantitative analysis

PRQR Key Highlights

• Market capitalization of $174.81M reflects investor sentiment regarding ProQR's pipeline and potential.
• Gross margin of 95.8% indicates strong potential profitability upon successful commercialization of products.
• Profit margin of -264.9% highlights the company's current reliance on R&D spending and lack of revenue-generating products.
• Beta of 0.09 suggests the stock is significantly less volatile than the overall market.
• Lead programs, sepofarsen and ultevursen, are in Phase II/III clinical trials, representing key milestones in their development.

Who Are PRQR's Competitors?

PRQR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PRQR's Key Strengths?

• Proprietary RNA-based therapeutic platform.
• Focus on rare genetic disorders with high unmet needs.
• Lead programs in Phase II/III clinical trials.
• Strategic collaborations with major pharmaceutical companies.

What Are PRQR's Weaknesses?

• High R&D costs and long development timelines.
• Reliance on clinical trial success and regulatory approvals.
• Negative profit margin and limited revenue generation.
• Small market size for some target indications.

What Could Drive PRQR Stock Higher?

• Data readout from the Phase II/III ILLUMINATE trial of sepofarsen for LCA10.
• Data readout from the Phase II/III trial of ultevursen for USH2A-mediated retinitis pigmentosa and Usher syndrome.
• Advancement of the Axiomer RNA base-editing platform and potential for new clinical programs.
• Progress in the collaboration with Eli Lilly and Company for genetic disorders in the liver and nervous system.

What Are the Key Risks for PRQR?

• Financial-distress signal — its Altman Z-Score of -5.83 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-86.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for sepofarsen or ultevursen.
• Regulatory setbacks or delays in obtaining FDA/EMA approval.
• Competition from other companies developing therapies for similar indications.
• High R&D costs and the need for additional financing.
• Patent challenges or intellectual property disputes.

What Are the Growth Opportunities for PRQR?

• Expansion of Axiomer Platform: ProQR's Axiomer RNA base-editing platform represents a significant growth opportunity. This technology could potentially address a wider range of genetic disorders beyond the company's current pipeline. The market for gene editing technologies is projected to reach billions of dollars in the coming years, offering substantial revenue potential for ProQR if the Axiomer platform proves successful. Timeline for expansion depends on ongoing research and development, with potential for new clinical programs in the next 3-5 years.
• Advancement of Sepofarsen: The successful completion of the Phase II/III ILLUMINATE trial for sepofarsen in treating Leber congenital amaurosis 10 (LCA10) represents a major growth catalyst. Positive trial results could lead to regulatory approval and commercialization, generating significant revenue. The market for LCA treatments is relatively small but underserved, offering potential for high pricing. The timeline for potential FDA/EMA approval is approximately 1-2 years following successful trial completion.
• Progression of Ultevursen: The ongoing Phase II/III clinical trial for ultevursen in treating USH2A-mediated retinitis pigmentosa and Usher syndrome is another key growth driver. Positive clinical data could lead to regulatory approval and commercial launch, addressing a significant unmet need in the treatment of these inherited retinal diseases. The market for Usher syndrome treatments is substantial, with a large patient population. The timeline for potential regulatory approval is similar to sepofarsen, contingent on successful trial outcomes.
• Strategic Partnerships: ProQR's collaboration with Eli Lilly and Company to discover, develop, and commercialize potential new medicines for genetic disorders in the liver and nervous system provides a significant growth opportunity. This partnership could generate upfront payments, milestone payments, and royalties on future product sales, providing a valuable source of revenue and expertise. The timeline for potential product launches resulting from this collaboration is uncertain but could extend over several years.
• Geographic Expansion: ProQR's current focus is primarily on the US and European markets. Expanding into other geographic regions, such as Asia and Latin America, could provide additional growth opportunities. These regions have large patient populations with genetic disorders and increasing access to healthcare. The timeline for geographic expansion depends on regulatory approvals and market access strategies, but could occur within the next 3-5 years.

What Opportunities Does PRQR Have?

• Expansion of Axiomer platform to address a wider range of genetic disorders.
• Potential for breakthrough therapies in underserved markets.
• Strategic partnerships to accelerate drug development and commercialization.
• Geographic expansion into new markets.

What Threats Does PRQR Face?

• Clinical trial failures and regulatory setbacks.
• Competition from other biotechnology and pharmaceutical companies.
• Changes in regulatory landscape and reimbursement policies.
• Patent challenges and intellectual property disputes.

What Are PRQR's Competitive Advantages?

• Proprietary RNA-based therapeutic technologies.
• Strong intellectual property protection (patents).
• Focus on rare diseases with limited competition.
• Strategic partnerships with leading pharmaceutical companies.
• Expertise in RNA biology and drug development.

What Does PRQR Do?

ProQR Therapeutics N.V., established in 2012 and headquartered in Leiden, the Netherlands, is a biopharmaceutical company dedicated to discovering and developing RNA-based therapeutics for the treatment of genetic disorders. The company's primary focus is on addressing rare diseases with significant unmet medical needs. ProQR's lead product candidates include sepofarsen, currently in Phase II/III clinical trials (ILLUMINATE trial) for Leber congenital amaurosis 10 (LCA10) caused by the p.Cys998X mutation in the CE290 gene, and ultevursen, also in Phase II/III clinical trials, targeting USH2A-mediated retinitis pigmentosa and Usher syndrome. These programs leverage ProQR's expertise in RNA technology to develop therapies that target the underlying genetic causes of these diseases. In addition to its clinical-stage programs, ProQR is also developing its Axiomer RNA base-editing platform technology, which has the potential to address a wider range of genetic disorders. ProQR has established strategic collaborations to bolster its research and development efforts, including license agreements with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, the company has a license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR's focus on RNA-based therapies and its strategic partnerships position it as an innovator in the biotechnology industry.

What Products and Services Does PRQR Offer?

• Develops RNA-based therapeutics for genetic disorders.
• Focuses on rare diseases with high unmet medical needs.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Utilizes its Axiomer RNA base-editing platform to discover new therapies.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Collaborates with other companies and research institutions to advance its pipeline.
• Aims to commercialize its products and make them available to patients.

How Does PRQR Make Money?

• Develops and patents RNA-based therapeutic technologies.
• Conducts clinical trials to demonstrate efficacy and safety.
• Out-licenses or co-develops therapies with larger pharmaceutical companies.
• Seeks regulatory approval for commercialization.
• Generates revenue through product sales, licensing agreements, and milestone payments.

What Industry Does PRQR Operate In?

ProQR Therapeutics operates within the biotechnology industry, which is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The market for RNA-based therapeutics is growing, driven by advancements in technology and a better understanding of disease mechanisms. ProQR's focus on rare genetic disorders positions it within a niche market with potentially high pricing power, but also limited patient populations. The company competes with other biotechnology companies developing therapies for similar indications, as well as larger pharmaceutical companies with broader pipelines and resources. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.

Who Are PRQR's Key Customers?

• Patients suffering from rare genetic disorders.
• Healthcare providers who treat these patients.
• Pharmaceutical companies seeking to expand their product portfolios.
• Research institutions interested in collaborating on drug development.
• Payers (insurance companies and government healthcare programs) who reimburse for treatments.

ROE -87%Key Financial Metrics

Return on equity for ProQR Therapeutics N.V. stands at -86.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -46.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -31.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.0%, the inverse of the P/E and a quick read on earnings relative to price.

ProQR Therapeutics N.V. (PRQR) Valuation Context

Valued at $174.81M, PRQR is classified as a micro-cap stock. Relative to its peer group, PRQR's quantitative score of 52/100 is below the peer average of 68/100.

Company Profile

ProQR Therapeutics N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Leiden, NL. The company is led by CEO Daniel Anton de Boer. PRQR has traded publicly since 2014.

F-Score 0/9Financial Health

ProQR Therapeutics N.V.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.83 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project ProQR Therapeutics N.V. revenue of about $13.4M for fiscal 2026, with EPS near $-0.46. The estimate reflects 5 contributing analysts.

PRQR Financials

PRQR Latest News

PRQR Analyst Consensus

PRQR MoonshotScore

ProQR Therapeutics N.V. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources